Search
Talphera Inc
TLPHAdd to Watchlist
1.305USD
+0.045+3.57%
Close 07-28 16:00（ET）Quotes delayed by 15 min
65.32MMarket Cap
LossP/E TTM
More Details of Talphera Inc Company
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Talphera Inc Info
Ticker SymbolTLPH
Company nameTalphera Inc
IPO dateFeb 11, 2011
CEOAngotti (Vincent J)
Number of employees13
Security typeOrdinary Share
Fiscal year-endFeb 11
Address1850 Gateway Drive
CitySAN MATEO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16502163500
Websitehttps://talphera.com/
Ticker SymbolTLPH
IPO dateFeb 11, 2011
CEOAngotti (Vincent J)
Company Executives of Talphera Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
45.03K
-5.43%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
20.87K
-21.65%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
18.44K
+27.65%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
11.50K
+44.36%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
9.69K
+52.62%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
7.85K
+64.94%
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
45.03K
-5.43%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
20.87K
-21.65%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
18.44K
+27.65%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
11.50K
+44.36%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
9.69K
+52.62%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
7.85K
+64.94%
FAQs
Who are the top five shareholders of Talphera Inc?
The top five shareholders of Talphera Inc are: Mr. Badri N. Dasu
How many institutions hold shares of Talphera Inc (TLPH)?
As of 2026Q1, 68 institutions hold shares of Talphera Inc, with a combined market value of approximately 20.36M, accounting for 40.00% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 746542.00.
What is the biggest source of revenue for Talphera Inc?
In 2026Q1, the DSUVIA business generated the highest revenue for Talphera Inc, amounting to 1.59M and accounting for 89.67% of total revenue.